Serum soluble tumor necrosis factor-like weak inducer of apoptosis is a potential biomarker for outcome prediction of patients with aneurysmal subarachnoid hemorrhage
| Autor: | Sun Jun, Lin Qun, Jun-Xia Dai, Cai Jianyong, Zheng-Quan Yu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Multivariate analysis Subarachnoid hemorrhage Clinical Biochemistry Apoptosis Inflammation Biochemistry Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Inducer Prospective Studies Receiver operating characteristic business.industry Glasgow Outcome Scale Biochemistry (medical) General Medicine Subarachnoid Hemorrhage Prognosis medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Tumor necrosis factor alpha medicine.symptom business Biomarkers |
| Zdroj: | Clinica Chimica Acta. 510:354-359 |
| ISSN: | 0009-8981 |
| DOI: | 10.1016/j.cca.2020.07.052 |
| Popis: | Background Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) might contribute to brain inflammation after acute brain injury. The current study was designed to investigate whether serum soluble TWEAK (sTWEAK) can serve as a potential biomarker for functional outcome after aneurysmal subarachnoid hemorrhage (aSAH). Methods In this single-center prospective, observational study, admission serum sTWEAK concentrations were quantified among 112 aSAH patients. Impact of serum sTWEAK concentrations on a poor outcome (Glasgow outcome scale score 1–3) at 6 months after stroke onset was determined using multivariate analysis. Results Admission serum sTWEAK concentrations were intimately correlated with serum C-reactive protein concentrations, World Federation of Neurological Surgeons scores and modified Fisher scores. A total of 38 patients (33.9%) had a poor outcome at post-hemorrhagic 6 months. Admission serum sTWEAK concentrations were substantially higher in patients with a poor outcome than in the other remainders. Under receiver operating characteristic curve, serum sTWEAK concentrations significantly distinguished a poor outcome. Serum sTWEAK concentrations > 3.23 ng/ml discriminated the risk of a poor outcome with medium-high sensitivity and specificity and independently predicted a poor outcome. Conclusions Serum sTWEAK, in close correlation with inflammation and hemorrhagic severity, might represent a potential biomarker for predicting clinical outcome after aSAH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect